Pseudomonas aeruginosa is related to the severe respiratory tract and bloodstream infections and lately has become resistant to many major classes of antibiotics.
At present, a combination of antibiotics is used to battle Pseudomonas aeruginosa. However, these infections have gotten increasingly tough to treat, as resistance to last-line antibiotics is being observed.
To evaluate the synergy of EGCG and aztreonam, Dr. Betts and co-authors performed in vitro checks to analyze how they interacted with Pseudomonas aeruginosa, individually and together.
They discovered that the combination of aztreonam and EGCG was significantly effective at reducing Pseudomonas aeruginosa numbers than either agent alone.
This synergistic activity was additionally confirmed in vivo utilizing Galleria mellonella, with survival rates being significantly higher in those treated with the combination than these treated with EGCG or aztreonam alone.
Furthermore, minimal to no toxicity was noticed in human skin cells and Galleria mellonella larvae.
The researchers consider that in Pseudomonas aeruginosa, EGCG could facilitate increased uptake of aztreonam by increasing permeability in the bacteria. Another potential mechanism is EGCG’s interference with a biochemical pathway linked to antibiotic susceptibility.
“Antimicrobial resistance (AMR) is a serious hazard to global public health. Without effective antibiotics, the success of medical treatments can be compromised,” Dr. Betts mentioned.
“Natural products similar to EGCG, used in mixture with currently licensed antibiotics, maybe a method of improving their effectiveness and clinically helpful lifespan.”